Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Safety and hemostatic efficacy of fibrin pad in partial nephrectomy: Results of an open-label Phase I and a randomized, standard-of-care-controlled Phase I/II study

  • Ofer Nativ1,
  • Bababhai Patel2,
  • Jessica Shen2,
  • Jonathan Batiller2,
  • Sara Horn3 and
  • James C Hart2Email author
BMC Nephrology201213:147

DOI: 10.1186/1471-2369-13-147

Received: 18 June 2012

Accepted: 30 October 2012

Published: 8 November 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
18 Jun 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
6 Jul 2012 Author responded Author comments - James Hart
Resubmission - Version 4
6 Jul 2012 Submitted Manuscript version 4
27 Jul 2012 Reviewed Reviewer Report - Brian Lane
11 Aug 2012 Reviewed Reviewer Report - Saleh Binsaleh
19 Aug 2012 Reviewed Reviewer Report - Lissy Krishnan
11 Oct 2012 Author responded Author comments - James Hart
Resubmission - Version 5
11 Oct 2012 Submitted Manuscript version 5
Publishing
30 Oct 2012 Editorially accepted
8 Nov 2012 Article published 10.1186/1471-2369-13-147

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Bnai Zion Medical Center
(2)
Ethicon, Inc, A Johnson and Johnson Company
(3)
Omrix Biopharmaceuticals Ltd

Advertisement